Update on rifampin and rifabutin drug interactions

被引:102
作者
Baciewicz, Anne M. [1 ]
Chrisman, Cary R. [2 ]
Finch, Christopher K. [3 ,4 ]
Self, Timothy H. [3 ,4 ]
机构
[1] Johns Hopkins Bayview Med Ctr, Dept Pharm, Baltimore, MD USA
[2] Methodist Med Ctr Oak Ridge, Oak Ridge, TN USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA
[4] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Methodist Univ Hosp, Memphis, TN 38163 USA
关键词
rifampin; rifabutin; drug interactions;
D O I
10.1097/MAJ.0b013e31814a586a
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Examples of clinically relevant interactions demonstrated by recent reports include everolimus, atorvastatin, rosiglitazone/pioglitazone, celecoxib, clarithromycin, caspofungin, and lorazepam. To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Studies and cases of rifampin drug interactions continue to increase rapidly. This review is a timely reminder to clinicians to be vigilant.
引用
收藏
页码:126 / 136
页数:11
相关论文
共 70 条
[41]  
Orisakwe Orish E, 2004, Am J Ther, V11, P171, DOI 10.1097/00045391-200405000-00004
[42]  
Orisakwe Orish E, 2004, Am J Ther, V11, P13, DOI 10.1097/00045391-200401000-00006
[43]  
Orisakwe Orish E, 2004, Am J Ther, V11, P283, DOI 10.1097/01.mjt.0000117523.18923.4a
[44]   Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin [J].
Paine, MF ;
Wagner, DA ;
Hoffmaster, KA ;
Watkins, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :524-535
[45]   Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects [J].
Park, JY ;
Kim, KA ;
Kang, MH ;
Kim, SL ;
Shin, JG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) :157-162
[46]   Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide [J].
Park, JY ;
Kim, KA ;
Park, PW ;
Park, CW ;
Shin, JG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (04) :334-340
[47]   Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria [J].
Pukrittayakamee, S ;
Prakongpan, S ;
Wanwimolruk, S ;
Clemens, R ;
Looareesuwan, S ;
White, NJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1509-1513
[48]  
RAMACHANDRAN G, 2006, J ACQ IMMUN DEF SYND, V41, P36
[49]   Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HV-infected patients with standard tuberculosis therapy (TBQD study) [J].
Ribera, E ;
Azuaje, C ;
Lopez, RM ;
Domingo, P ;
Soriano, A ;
Pou, L ;
Sánchez, P ;
Mallolas, J ;
Sambea, MA ;
Falco, V ;
Ocaña, I ;
Lopez-Colomes, JL ;
Gatell, JM ;
Pahissa, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) :317-323
[50]   Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients [J].
Ribera, E ;
Pou, L ;
Fernandez-Sola, A ;
Campos, F ;
Lopez, RM ;
Ocaña, I ;
Ruiz, I ;
Pahissa, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3238-3241